ABBOTT IRELAND ARCHITECT AFP REAGENT KIT; KIT, TEST, ALPHA-FETOPROTEIN FOR NEURAL TUBE DEFECTS
|
Back to Search Results |
|
Model Number 3P36-25 |
Device Problem
Low Test Results (2458)
|
Patient Problem
No Clinical Signs, Symptoms or Conditions (4582)
|
Event Date 06/10/2022 |
Event Type
malfunction
|
Manufacturer Narrative
|
Patient identifier: sid (b)(6) and sid (b)(6).An evaluation is in process.A follow-up report will be submitted when the evaluation is complete.
|
|
Event Description
|
The customer observed falsely depressed architect afp results for one patient.The initial result in question for sid (b)(6) on (b)(6) 2022 was 187.19 ui/ml.A new sample sid (b)(6) from (b)(6) 2022 generated a result of >1660.00, dilution 1:10 >16600.00, dilution 1:20 18584.24 ui/ml.The sample from (b)(4) 2022 (sid (b)(6)) was repeated on (b)(6) 2022 and the result was >1660.00, dilution 1:10 >16600.00, dilution 1:20 11463.05 ui/ml.No impact to patient management was reported.
|
|
Manufacturer Narrative
|
This follow up is being submitted to include the initial coding in section h6 for component code, type of investigation, investigation findings and investigation conclusions that were not included in the initial report.
|
|
Manufacturer Narrative
|
Data and information provided by the customer were reviewed and support the complaint issue.The ticket search by lot indicates that the reagent lot performs as expected for this product.Return testing was not performed as returns were not available.Device history record review was performed on lot 37040fn00, which did not show any potential non-conformances, deviations, or non-conformances.Trending review did not identify any trends for the complaint issue.Review of field data for the architect afp assays shows that the median patient result for lot 37040fn00 falls within 1sd of the established baseline, indicating the reagent lot is performing acceptably on market.As the expected result was obtained for a new sample draw and on repeat of the original sample, it is possible that reagent/sample integrity issues at the time of testing may have contributed to the false depressed result obtained.Details around specimen and reagent handling are outlined in the product package insert.A review of the labeling addresses the customer¿s issue.Per product labelling if the architect afp results are inconsistent with clinical evidence, additional testing is suggested to confirm the result.For diagnostic purposes, results should be used in conjunction with other data; e.G., symptoms, results of other tests, clinical impressions etc.Based on all reviewed data, we conclude that there is no product deficiency with the architect afp reagent identified in this complaint.
|
|
Search Alerts/Recalls
|
|
|